Peijun He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peijun He has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
B. Michael Ghadimi
6 shared publications- Dong Hoon Lee
American Institutes for Research, VA, USA
6 shared publications H. Richard Alexander
6 shared publicationsHarris G. Yfantis
6 shared publications- Jochen Gaedcke
Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany
6 shared publications - Nader Hanna
University of Maryland School of Medicine, Baltimore, MD
6 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1, S2, S3 from Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer
Figure S1: Representative pictures of immunohistochemical staining, showing NOSTRIN expression largely in the tumor cells in the patient with long survival. Figure S2: NOSTRIN overexpression sensitizes the Panc1 pancreatic cancer cells to gemcitabine. Figure S3: (a) A negative correlation existed between miR-222 and NOSTRIN expression in tumors from PDAC cases (N=37). (b) miR-222 expression does not show any significant association with survival. (ns=non significant).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1, S2, S3 from Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer
Figure S1: Representative pictures of immunohistochemical staining, showing NOSTRIN expression largely in the tumor cells in the patient with long survival. Figure S2: NOSTRIN overexpression sensitizes the Panc1 pancreatic cancer cells to gemcitabine. Figure S3: (a) A negative correlation existed between miR-222 and NOSTRIN expression in tumors from PDAC cases (N=37). (b) miR-222 expression does not show any significant association with survival. (ns=non significant).
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1, Figure 1 - 4 from FOXL1, a Novel Candidate Tumor Suppressor, Inhibits Tumor Aggressiveness and Predicts Outcome in Human Pancreatic Cancer
PDF file - 612K, Table S1. Characteristics of patient population. Figure S1. An inverse association between FOXL1 and ZEB1 expressions in pancreatic cancer cell lines. Figure S2. Oncomine analysis on differential expression of FOXL1 in multiple publicly available microarray datasets of pancreatic cancer. Figure S3. The effect of silencing FOXL1 by siRNA on cell growth, apoptosis and invasion in pancreatic cancer cells. Figure S4. The regulation of apoptosis-related gene expression by overexpression of FOXL1 in Panc1 cells.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1, Figure 1 - 4 from FOXL1, a Novel Candidate Tumor Suppressor, Inhibits Tumor Aggressiveness and Predicts Outcome in Human Pancreatic Cancer
PDF file - 612K, Table S1. Characteristics of patient population. Figure S1. An inverse association between FOXL1 and ZEB1 expressions in pancreatic cancer cell lines. Figure S2. Oncomine analysis on differential expression of FOXL1 in multiple publicly available microarray datasets of pancreatic cancer. Figure S3. The effect of silencing FOXL1 by siRNA on cell growth, apoptosis and invasion in pancreatic cancer cells. Figure S4. The regulation of apoptosis-related gene expression by overexpression of FOXL1 in Panc1 cells.
- 1 October 2021
- Published by Elsevier in Journal of Infection
- Vol. 84 (1) , 48-55
A SARS-CoV-2 nucleocapsid ELISA represents a low-cost alternative to lateral flow testing for community screening in LMI countries
- 1 October 2021
- Published by Elsevier in Journal of Infection
- Vol. 84 (1) , 48-55
A SARS-CoV-2 nucleocapsid ELISA represents a low-cost alternative to lateral flow testing for community screening in LMI countries